Cancer Treatments
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
694
NCT05304377
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
Phase: Phase 1
Role: Lead Sponsor
Start: May 22, 2022
Completion: Dec 31, 2026
NCT05650879
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
Start: Mar 20, 2023
Completion: Jul 31, 2026
NCT06328738
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Start: May 30, 2024
Completion: Jul 31, 2028
NCT06787144
ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Start: Jan 23, 2025
Completion: Jan 31, 2028
Loading map...